Pembrolizumab (Keytruda)

Key Messages

• CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses pembrolizumab (Keytruda), supplied as:
  • powder for solution for infusion: 50 mg lyophilized powder of pembrolizumab in a single-use vial, for reconstitution
  • solution for infusion: 100 mg/4 mL (25 mg/mL) solution in a single-use vial administered as an IV infusion over 30 minutes.
• Indication: Adjuvant treatment of adult patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.